Presenters include Dr. Amir Azadi of Barrow Neurological Institute , Dr. Nicholas Blondin of Yale University and Dr. Priya U. Kumthekar of Northwestern University SAN DIEGO --(BUSINESS WIRE)--Apr. 1, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products
SAN DIEGO --(BUSINESS WIRE)--Aug. 25, 2023-- Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call on August 30, 2023 , beginning at 4:00 p.m. Eastern time ( 1:00 p.m. Pacific time ) to provide a business update and to answer questions. Participants can pre-register for the conference
SAN DIEGO --(BUSINESS WIRE)--Jun. 7, 2022-- Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call today, June 7, 2022 , beginning at 4:00 p.m. Eastern time to discuss its re-focused and rationalized business strategy and to answer questions.
SAN DIEGO , May 5, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a leading molecular diagnostics company with a commercialized liquid biopsy technology, Target Selector TM , focused on cancer treatment and monitoring, announces that it will release financial results for the three months
SAN DIEGO , Oct. 29, 2015 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection and treatment of cancer, announces that it will release financial results for the quarter ended September
SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that it will release financial results for the quarter ended June 30, 2015 after market close on
SAN DIEGO , Feb. 29, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection and treatment of cancer, announces that it will release financial results for the three months and 12 months
SAN DIEGO --(BUSINESS WIRE)--Jan. 6, 2023-- Biocept, Inc. (NasdaqCM: BIOC ) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has engaged EF Hutton, division of Benchmark Investments, Inc.
SAN DIEGO --(BUSINESS WIRE)--Jun. 22, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced a collaboration with Quest Diagnostics (NYSE: DGX) to provide laboratory testing services to Quest patients for its Target Selector™
